BBGBloomberg·12hBusiness
score-0.60
Novartis Faces Growth Questions After Avidity Drug's Third Trial Setback
Original
Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
“Emphasizes repeated corporate failure and financial loss, framing the event as a significant setback to growth prospects.”